Investor Presentaiton

R&D CAPABILITIES R&D Expense (in million) 2,500 12% NATCO 14.0% R&D capabilities demonstrated by its complex and niche product filings in formulations and API segments 12.0% 2,000 9.3% 9.1% 8.7% 10.0% 8% 1,500 7.8% 8.0% 2,267 6.0% 1,000 1,976 1,950 1,665 1,656 1,596 4.0% 500 2.0% 0.0% FY18 FY19 FY20 FY21 FY22 FY23 R&D Expense R&D Expense% 8% 22% Two research facilities with capabilities across synthetic chemistry, nano pharmaceuticals, new drug discovery and cell biology Specialised R&D laboratories in two research facilities Talented Pool of Scientists: 465(1) 9% 4% FINISHED DOSAGE FORMULATIONS (FDF) (2) ACTIVE PHARMACEUTICAL INGREDIENTS (API)(2) 27% ■ AR & D 5% ■CR & D ■ Masters ■FR & D ■ Ph.D. ■ Others ■ NDDS ■RA 23 Para IV filings in pipeline 56 Cumulative DMFS filed 30% 70% Others 25% BREAKDOWN OF SCIENTISTS FY numbers have been prepared under Ind AS (1) As of March 31, 2023 2) As of Sept 30, 2023. Does not include integrated DMFS filed with ANDAS 15 approved Para IV (either tentative or final) 45 active DMFS 11

View entire presentation